Xtandi (enzalutamide) Articles

Articles

Amendment to Clinical Research Protocol for Phase III PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
- Amendment accelerates anticipated PROSPER top-line results by two years -

Truckee, CA.—(UroToday)—The amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of XTANDI® (enzalutamide) in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) was announced on June 9, 2017. The primary endpoint remains the same: metastasis-free survival (MFS).

Published June 10, 2017
FDA approves Xtandi (enzalutamide)

SILVER SPRING, MD USA (PRESS RELEASE) - August 31, 2012

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Published September 1, 2012